参考文献/References:
[1] Lin KH,Chiang JC,Ho YH,et al.Lysophosphatidic acid and hematopoiesis:from microenvironmental effects to intracellular signaling[J].Int J Mol Sci,2020,21(6):2015.
[2] Tabuchi S. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade:proposal of a novel potential therapeutic target for treating glioblastoma multiforme[Z], 2015:56.
[3] Wang C. Lysophosphatidic acid induces neuronal cell death via activation of asparagine endopeptidase in cerebral ischemia-reperfusion injury[Z], 2018:1-9.
[4] Yamada M.Lysophosphatidic acid induces anxiety-like behavior via its receptors in mice[J].J Neural Transm(Vienna),2015,122(3):487-494.
[5] Balijepalli P,Sitton CC,Meier KE.Lysophosphatidic acid signaling in cancer cells: what makes LPA so special?[J].Cells,2021,10(8):2059.
[6] Marchan R.Glycerol-3-phosphate acyltransferase 1 promotes tumor cell migration and poor survival in ovarian carcinoma[J].Cancer Res,2017,77(17):4589-4601.
[7] Irifune H.GPAM mediated lysophosphatidic acid synthesis regulates mitochondrial dynamics in acute myeloid leukemia[J].Cancer Sci,2023,114(8):3247-3258.
[8] Chen X. Correlation between Lpa,APO-A,APO-B,and stenosis of middle cerebral artery in patients with cerebral ischemic stroke[Z], 2022: 6403645.
[9] Weiss RH.Lysophosphatidic acid reduces microregional oxygen supply/consumption balance after cerebral ischemia-reperfusion[J].J Vasc Res,2020,57(4):178-184.
[10] Bhattarai S.Disrupted blood-brain barrier and mitochondrial impairment by autotaxin-lysophosphatidic acid axis in postischemic stroke[J].J Am Heart Assoc,2021,10(18):e021511.
[11] Chi ZO.Lysophosphatidic acid increased infarct size in the early stage of cerebral ischemia-reperfusion with increased BBB permeability[J].J Stroke Cerebrovasc Dis,2020,29(10):105029.
[12] Gao L.Inhibition of lysophosphatidic acid receptor 1 relieves PMN recruitment in CNS via LPA1/TSP1/CXCR2 pathway and alleviates disruption on blood-brain barrier following intracerebral haemorrhage in mice[J].Fluids Barriers CNS,2023,20(1):33.
[13] Pasic D M.Alzheimer disease:advances in pathogenesis,diagnosis,and therapy[J].Clin Chem,2011,57(5):664-669.
[14] Sharma P. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies[Z], 2019: 53-89.
[15] Wang LH. Age-related alterations of neuronal excitability and voltage-dependent Ca(2+)current in a spontaneous mouse model of Alzheimer's disease[Z], 2017: 209-213.
[16] Campese N.Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases[J].Expert Rev Proteomics,2021,18(1):27-48.
[17] Balmik AA,Chinnathambi S.Methylation as a key regulator of Tau aggregation and neuronal health in Alzheimer's disease[J].Cell Commun Signal,2021,19(1):51.
[18] Jevtic S. The role of the immune system in Alzheimer disease:etiology and treatment[Z], 2017: 84-94.
[19] Chen YKYF,Ip NY. Synaptic dysfunction in Alzheimer's disease:mechanisms and therapeutic strategies[Z], 2019: 186-198.
[20] Ramesh S,Govindarajulu M,Suppiramaniam V,et al.Autotaxin-lysophosphatidic acid signaling in Alzheimer's disease[J].Int J Mol Sci,2018,19(7):1827.
[21] Herr DR,Ong JHJ,Ong WY.Potential therapeutic applications for inhibitors of autotaxin, a bioactive lipid-producing lysophospholipase D, in disorders affecting the nervous system[J].ACS Chem Neurosci,2018,9(3):398-400.
[22] Herr RD.Pleotropic roles of autotaxin in the nervous system present opportunities for the development of novel therapeutics for neurological diseases[J].Mol Neurobiol,2020,57(1):372-392.
[23] Shi J.Lysophosphatidic acid induces increased BACE1 expression and Aβ formation[J].Biochim Biophys Acta,2013,1832(1):29-38.
[24] Zhang ZT,Song MK,Liu X,et al.Cleavage of Tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease[J].Nat Med,2014,20(11):1254-1262.
[25] Sayas LC.The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation[J].J Biol Chem,1999,274(52):37046-37052.
[26] Cong S. Prevalence and clinical aspects of depression in Parkinson's disease:a systematic review and meta-analysis of 129 studies[Z], 2022: 104749.
[27] Yang YX.LPA signaling is required for dopaminergic neuron development and is reduced through low expression of the LPA1 receptor in a 6-OHDA lesion model of Parkinson's disease[J].Neurol Sci,2015,36(11):2027-2033.
[28] Choi HJ. Multi-target protective effects of gintonin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-mediated model of Parkinson's disease via lysophosphatidic acid receptors[Z], 2018: 515.
[29] Zou L. Asparagine endopeptidase cleaves synaptojanin 1 and triggers synaptic dysfunction in Parkinson's disease[Z], 2021: 105326.
[30] Zhang ZT,Kang SS,Liu X,et al.Asparagine endopeptidase cleaves α-synuclein and mediates pathologic activities in Parkinson's disease[J].Nat Struct Mol Biol,2017,24(8):632-642.
[31] Oh JA,Vidal-Jordana,Montalban X.Multiple sclerosis:clinical aspects[J].Curr Opin Neurol,2018,31(6):752-759.
[32] Sand K,Classification I.And differential diagnosis of multiple sclerosis[J].Curr Opin Neurol,2015,28(3):193-205.
[33] Fransson J.Activation of macrophages by lysophosphatidic acid through the lysophosphatidic acid receptor 1 as a novel mechanism in multiple sclerosis pathogenesis[J].Mol Neurobiol,2021,58(2):470-482.
[34] Shimizu Y. Quantitative determination of cyclic phosphatidic acid and its carba analog in mouse organs and plasma using LC-MS/MS[Z], 2018: 15-21.
[35] Schmitz K.Dysregulation of lysophosphatidic acids in multiple sclerosis and autoimmune encephalomyelitis[J].Acta Neuropathol Commun,2017,5(1):42.
[36] Balood M.Elevated serum levels of lysophosphatidic acid in patients with multiple sclerosis[J].Hum Immunol,2014,75(5):411-413.
[37] Zahednasab H.Increased autotaxin activity in multiple sclerosis[J].J Neuroimmunol,2014,273(1/2):120-123.
[38] Choi HJ. Gintonin mitigates experimental autoimmune encephalomyelitis by stabilization of Nrf2 signaling via stimulation of lysophosphatidic acid receptors[Z], 2021: 384-398.
[39] Castilla-Ortega E,Escuredo L,Bilbao A,et al.1-Oleoyl lysophosphatidic acid: a new mediator of emotional behavior in rats[J].PLoS One,2014,9(1):e85348.
[40] Santin JL.Behavioral phenotype of maLPA1-null mice:increased anxiety-like behavior and spatial memory deficits[J].Genes Brain Behav,2009,8(8):772-784.
[41] Rosell-Valle C,Martínez-Losa M,Matas-Rico E,et al.GABAergic deficits in absence of LPA1 receptor, associated anxiety-like and coping behaviors, and amelioration by interneuron precursor transplants into the dorsal hippocampus[J].Brain Struct Funct,2021,226(5):1479-1495.
[42] Pedraza C.Fear extinction and acute stress reactivity reveal a role of LPA(1)receptor in regulating emotional-like behaviors[J].Brain Struct Funct,2014,219(5):1659-1672.
[43] Lin YN,Audira G,Malhotra N,et al.A novel function of the lysophosphatidic acid receptor 3(LPAR3)gene in zebrafish on modulating anxiety,circadian rhythm locomotor activity,and short-term memory[J].Int J Mol Sci,2020,21(8):2837.
[44] Zhang YC,Ma L. Depression and cardiovascular disease in elderly:current understanding[Z], 2018: 1-5.
[45] Amasi-Hartoonian AN. Understanding treatment-resistant depression using "omics" techniques:a systematic review[Z], 2022: 423-455.
[46] Itagaki K.Reduced serum and cerebrospinal fluid levels of autotaxin in major depressive disorder[J].Int J Neuropsychopharmacol,2019,22(4):261-269.
[47] Omori W.Reduced cerebrospinal fluid levels of lysophosphatidic acid docosahexaenoic acid in patients with major depressive disorder and schizophrenia[J].Int J Neuropsychopharmacol,2021,24(12):948-955.
[48] Riya S.Evaluation of serum lysophosphatidic acid and lysophosphatidylcholine levels in major depressive disorder patients[J].Cureus,2020,12(12):e12388.
[49] Gotoh L.Lysophosphatidic acid levels in cerebrospinal fluid and plasma samples in patients with major depressive disorder[J].Heliyon,2019,5(5):e01699.
[50] Nagata W.Treatment with lysophosphatidic acid prevents microglial activation and depression-like behaviours in a murine model of neuropsychiatric systemic lupus erythematosus[J].Clin Exp Immunol,2023,212(2):81-92.
[51] Hisaoka-Nakashima HK. Mirtazapine increases glial cell line-derived neurotrophic factor production through lysophosphatidic acid 1 receptor-mediated extracellular signal-regulated kinase signaling in astrocytes[Z], 2019: 172539.
[52] Faden J,Citrome L.Schizophrenia: one Name, many different manifestations[J].Med Clin North Am,2023,107(1):61-72.
[53] Stamu-O'Brien C,Kroumpouzos G.The role of lipids in vitiligo and schizophrenia[J].Clin Dermatol,2023,41(1):89-94.
[54] Mirendil H.LPA signaling initiates schizophrenia-like brain and behavioral changes in a mouse model of prenatal brain hemorrhage[J].Transl Psychiatry,2015,5(4):e541.
[55] Thalman C.Synaptic phospholipids as a new target for cortical hyperexcitability and E/I balance in psychiatric disorders[J].Mol Psychiatry,2018,23(8):1699-1710.
[56] Musazzi L.Abnormalities in α/β-CaMKII and related mechanisms suggest synaptic dysfunction in hippocampus of LPA1 receptor knockout mice[J].Int J Neuropsychopharmacol,2011,14(7):941-953.
[57] Stokosa I,Wickiewicz G,Stokosa M,et al.Medications for the treatment of alcohol dependence-current state of knowledge and future perspectives from a public health perspective[J].Int J Environ Res Public Health,2023,20(3):1870.
[58] García-Marchena N,Pizarro N,Pavón FJ,et al.Potential association of plasma lysophosphatidic acid(LPA)species with cognitive impairment in abstinent alcohol use disorders outpatients[J].Sci Rep,2020,10(1):17163.
[59] Flores-López M,García-Marchena N,Araos P,et al.Sex differences in plasma lysophosphatidic acid species in patients with alcohol and cocaine use disorders[J].Brain Sci,2022,12(5):588.
[60] Flores-López M,García-Marchena N,Pavon FJ,et al.Plasma concentrations of lysophosphatidic acid and autotaxin in abstinent patients with alcohol use disorder and comorbid liver disease[J].Biomedicines,2021,9(9):1207.
[61] Castilla-Ortega CE. Both genetic deletion and pharmacological blockade of lysophosphatidic acid LPA1 receptor results in increased alcohol consumption[Z], 2016: 92-103.